SIREN L L C
Q1 2026 Form 13-F
GREENWICH, DELAWARE
CIK 0002005245
· Institutional investment manager
Consolidated report · includes
2 managers
since Q3 2024
$3.6B Reported Value Total
Reported value
$3.6B
Quarter over quarter
+8.5%
Holdings
100
Top-10 concentration
49.8%
Filing Structure
Reports holdings for
- Invus Financial Advisors LLC · File #028-19938 · since Q3 2024
- Invus Group, LLC (not a 13F filer in our records) · File #028-24462 · since Q3 2024
Key People
Named on the latest Form 13-F filing — not necessarily an owner
Raymond Debbane
President
Filing Navigation
13F Metrics
Loading 13F Metrics
Q1 2026 13F record
Q1 2026 13F filing summary
| Period of report | March 31, 2026 |
|---|---|
| Filed | May 14, 2026 |
| Form | 13F-HR |
| Reported value | $3.6B |
| Positions | 100 |
| Change in reported value | +7.6% |
| New positions | 19 |
| Exited positions | 32 |
| Position turnover | 38.6% |
| Top-10 concentration | 49.8% |
13F filings by quarter
| Quarter | Positions | Value |
|---|---|---|
|
Q3 2026 13F
Filed Nov 12, 2026
|
110 | $4.2B |
|
Q2 2026 13F
Filed Aug 13, 2026
|
115 | $4.9B |
|
Q1 2026 13F
Filed May 14, 2026
|
100 | $3.6B |
|
Q4 2025 13F
Filed Feb 13, 2026
|
113 | $3.4B |
|
Q3 2025 13F
Filed Nov 13, 2025
|
115 | $2.6B |
|
Q2 2025 13F
Filed Aug 13, 2025
|
110 | $1.9B |
|
Q1 2025 13F
Filed May 14, 2025
|
116 | $1.8B |
|
Q4 2024 13F
Filed Feb 14, 2025
|
117 | $2.3B |
|
Q3 2024 13F
Filed Nov 13, 2024
|
109 | $2.0B |
Top 20 holdings · Q1 2026
| # | Holding | Reported value | % of portfolio |
|---|---|---|---|
| 1 | SRRK Scholar Rock Holding Corp | $532.2M | 14.75% |
| 2 | KYMR Kymera Therapeutics Inc | $265.4M | 7.36% |
| 3 | ERAS Erasca Inc | $181.9M | 5.04% |
| 4 | EWTX Edgewise Therapeutics Inc | $139.6M | 3.87% |
| 5 | ONC BeOne Medicines AG | $138.1M | 3.83% |
| 6 | TNGX Tango Therapeutics Inc | $118.3M | 3.28% |
| 7 | BCAX Bicara Therapeutics Inc | $115.4M | 3.2% |
| 8 | RVMD Revolution Medicines Inc | $108.0M | 3.0% |
| 9 | ARWR Arrowhead Pharmaceuticals Inc | $101.3M | 2.81% |
| 10 | MANE Veradermics Inc | $95.1M | 2.64% |
| 11 | XENE Xenon Pharmaceuticals Inc | $76.7M | 2.13% |
| 12 | OLMA Olema Pharmaceuticals Inc | $70.9M | 1.97% |
| 13 | CRNX Crinetics Pharmaceuticals Inc | $69.1M | 1.92% |
| 14 | LXRX Lexicon Pharmaceuticals Inc | $69.1M | 1.92% |
| 15 | COGT Cogent Biosciences Inc | $65.8M | 1.82% |
| 16 | STOK Stoke Therapeutics Inc | $65.0M | 1.8% |
| 17 | RCUS Arcus Biosciences Inc | $65.0M | 1.8% |
| 18 | GPCR Structure Therapeutics Inc | $64.0M | 1.78% |
| 19 | IRON Disc Medicine Inc | $63.2M | 1.75% |
| 20 | RYTM Rhythm Pharmaceuticals Inc | $63.1M | 1.75% |
Values as reported on the Q1 2026 Form 13F. Every position is in the holdings table below.